DTC Marketing Analytics for Pharma & Medical Devices | Freshpaint

Solutions for Pharma & Medical Device Marketers

Grow DTC Campaigns. Protect Patient Data. Prove Performance Across the Full Patient Journey.

The leading privacy-first marketing platform built for pharma and medical device marketers. Freshpaint helps preserve attribution for direct-to-patient scripts, device adoption, and patient recruitment, making it easier to measure ROI across fragmented channels and reduce privacy risk under evolving compliance laws.

The Results Pharma & Device Marketers Achieve with Freshpaint

Reduce patient acquisition costs, connect campaigns to scripts and device activations, and mitigate FTC exposure, all while measuring performance across your entire DTC funnel.

Why DTC Pharma & Device Marketing Is Under Fire

Direct-to-consumer campaigns are surging, but so is regulatory scrutiny. The FTC is paying closer attention. State attorneys general are filing cases. Class action lawyers are targeting pixels. And the "we're not HIPAA-covered" is no longer a viable defense. The margin for error is shrinking as you’re asked to prove ROI while protecting patient data across clinical trial recruitment, telehealth redirects, and co-pay programs.

FTC & State Regulators Target Non-HIPAA Entities

HIPAA exemption doesn't equal safety. The FTC fined GoodRx $1.5M for sharing health data with ad platforms, and California's Healthline case extended state privacy laws to content publishers. Pharma brands are now facing class action lawsuits over co-pay program pixels, patient assistance sites, and branded content, even when HIPAA does not apply.

Fragmented Measurement Across DTC Channels

DTC campaigns run across social, CTV, programmatic, and endemic sites, but fragmented performance data makes it hard to prove outcomes. When attribution breaks at telehealth redirects and fulfillment partners, you can't connect ad spend to scripts filled or devices activated, making leadership question every dollar.

Risky Pixels Throughout Patient Acquisition Funnels

Standard Meta and Google pixels fire on branded sites, co-pay eligibility pages, telehealth partner handoffs, pharmacy fulfillment redirects, and device trial kit requests. These pixels capture patient intent tied to specific conditions, creating privacy risk under federal and state laws. Taking pixels down feels like the safest move, but it also makes campaigns harder to optimize and measure.

The Freshpaint Platform for Pharma & Device Marketers

Solutions That Transform DTC Marketing

Freshpaint solves the privacy-performance gap for pharma and device brands. It mitigates FTC and state law exposure, measures marketing impact to connect campaigns to real outcomes, and improves performance with safe audience targeting that does not trigger enforcement.

Improve Marketing Performance

Product Spotlight: Audiences

Build and activate high-intent audiences from patient data and real on-site behavior, without exposing sensitive health context.

Measure Marketing Impact

Connect ad spend to real business outcomes (e.g., scripts filled, devices activated, subjects recruited, patient enrollments completed). Freshpaint brings fragmented performance data together across all your social, CTV, programmatic, and endemic sites. This makes it possible to prove marketing ROI with attribution that actually reflects the complete patient journey.

Protect Privacy & Compliance

Mitigate FTC enforcement risk and state law violations from your entire DTC funnel. Freshpaint replaces risky pixels, scripts, and trackers with a single compliant pixel across branded sites, clinical trial landing pages, co-pay programs, telehealth redirects, and trial kit flows. This helps you maintain full marketing capabilities while staying safe from evolving privacy laws.

Proven Results

Real Impact From Leading Healthcare Organizations

Rebuilding DTC Performance With Privacy-First Tracking

When a major medical device brand was forced to remove traditional tracking for compliance reasons, their direct-to-consumer performance stalled overnight.

Result That matter

90% CPL Reduction Freshpaint restored privacy-safe conversion signals that ad platforms could actually optimize against, bringing CPL from $5,000+ to ~$500.

Purpose-Built for How You Market

From brand awareness through conversion and fulfillment, Freshpaint protects the high-risk touchpoints throughout your DTC patient acquisition funnel.

The Freshpaint Difference

Why Pharma & Device Brands Choose Freshpaint

From lawsuits and enforcement actions to shifting platform policies, the DTC environment has changed. Success now requires measurement approaches that protect performance while meeting higher standards for privacy. Freshpaint gives teams the best of both worlds.

Designed for Regulated DTC Marketing Realities

Unlike traditional tracking tools that can release sensitive health data downstream, Freshpaint supports privacy-first DTC measurement by giving brands greater control and visibility into how data is collected and shared. This lets teams continue running performance-driven DTC campaigns while meeting higher standards for privacy across educational, awareness, and conversion experiences.

Ready to Grow DTC Campaigns Without FTC Risk?

Join leading pharmaceutical and medical device brands using Freshpaint to track the complete direct-to-patient journey, prove marketing ROI, and eliminate regulatory exposure—all while scaling DTC growth with confidence.